Year: 2021
BERGENBIO announces EXCLUSIVE in-licensE of key intellectual property rights from ut Southwestern Medical center
In-Licensing further strengthens intellectual property estate for the treatment of Non-Small Cell Cancer (NSCLC) patients…
Read MoreBERGENBIO PRESENTS UPDATED Bemcentinib AML DATA at ASH 2021 MEETING
Bergen, Norway, 13 December 2021 – BerGenBio ASA (OSE:BGBIO), BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical…
Read MoreBERGENBIO ASA: RESULTS FOR THE THIRD QUARTER OF 2021
Bergen, Norway, 16 November 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel,…
Read MoreBERGENBIO PRESENTS PRE-CLINICAL AND CLINICAL data on BEMCENTINIB IN STK11-POSITIVE NSCLC at SITC Annual Meeting 2021
Bergen, Norway, 9 November 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective…
Read MoreBERGENBIO RECEIVES FDA FAST TRACK DESIGNATION FOR BEMCENTINIB in STK11-mutated advanced/metastatic Non-small cell lung cancer (NSCLC)
Bergen, Norway, 9 November 2021 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL…
Read More
BERGENBIO ASA: LEADERSHIP CHANGE
Bergen, Norway, 22 August 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL…
Read More
